Our promise to you:
Guaranteed product quality, expert customer support.
Virus infection is a severe public health problem with significant personal, social, and economical consequences. Current treatment of viral infections has relied on pre-emptive vaccination or use of a limited range of anti-viral drugs. However, the control of viral infection is difficult and complex because of the limited effectiveness of existing anti-viral agents and the high speed of mutation rate of the viral genome. More effective approaches are urgently needed to treat viral infection.
RNA-based therapeutics has been suggested as one of the most innovative approaches to derive an advance in the field of drug and vaccine development against the infectious diseases, including respiratory syncytial virus (RSV), HIV-1, rotavirus, baculoviruses, hepatitis B virus (HBV), hepatitis C virus (HCV) and influenza virus.
siRNA can be used to protect host from viral infection, inhibit the expression of viral antigen and accessory genes, control the transcription and replication of viral genome, hinder the assembly of viral particles, and display influences in virus-host interactions. Investigations suggested that siRNA-directed CD4 and CCR5 silencing specifically inhibit HIV-1 infection. These imply that siRNA-based drugs emerge as effective strategies to protect human cells from viral infection.
The fast and simple manufacturing process makes mRNA a promising bioproduct that can potentially fill the gap between emerging infectious disease and the desperate need for effective vaccines. Although clinical trials of mRNA vaccines for infectious disease are still in their early age, some preclinical and clinical results demonstrate that prophylaxis and therapy with mRNA promises to be useful for preventing infectious disease and that mRNA vaccines are safe and tolerated in animal models and humans. For example, pilot clinical trials with DCs transfected with mRNA encoding various HIV-1 antigens, cellular molecules, or pp65 of human cytomegalovirus showed that mRNA vaccines are safe and that they elicited antigen-specific CD4+ and CD8+ T cell immune responses; however, no reduction of viral load was observed.
With the years of experience in RNA research, IntegrateRNA has been enriched in RNA synthesis, sequencing, microarray and functional analysis. We are very confident to provide the best and all-around RNA-related services for customers from all around the world.